Principles of Administration and Gram-Positive Flora
Rational pharmacotherapy of infectious diseases relies on the mandatory isolation and precise identification of the microorganism. Only after this step does the clinician select the drug of choice.
Among Gram-positive cocci, streptococci and staphylococci hold the greatest clinical significance. For Streptococcus and Pneumococcus, benzylpenicillin remains the gold standard of therapy.
The approach to treating infections caused by Staphylococcus depends strictly on its enzymatic activity and resistance profile:
- If the strain does not produce $\beta$-lactamase, benzylpenicillin is used.
- When $\beta$-lactamase is produced, oxacillin is prescribed.
- If methicillin-resistant strains (MRSA) are identified, vancomycin becomes the rescue agent.
Gram-positive bacilli also require a specific approach. For example, in anthrax (Bacillus anthracis), benzylpenicillin is most effective, whereas in diphtheria (Corynebacterium diphtheriae), macrolides are indicated.
Gram-Negative Microorganisms
Gram-negative flora often require broader-spectrum or specifically targeted agents.
- Cocci: Meningococcal infection (Neisseria meningitidis) responds well to benzylpenicillin. For gonorrhea (Neisseria gonorrhoeae), ceftriaxone and ciprofloxacin are the first-line agents.
- Enteric Group: To eradicate Escherichia coli, ciprofloxacin or third-generation cephalosporins are used. Infections caused by Salmonella and Shigella require ciprofloxacin. If meningitis is caused by Klebsiella, second-generation cephalosporins are indicated.
- Specific Bacilli: Pseudomonas aeruginosa exhibits high intrinsic resistance, so antipseudomonal penicillins (ureidopenicillins, carboxypenicillins) or ceftazidime are used against it. For pneumonia and meningitis caused by Haemophilus influenzae, third-generation cephalosporins, beta-lactamase inhibitor combinations (amoxicillin/clavulanate), or trimethoprim-sulfamethoxazole are prescribed.
Highly Hazardous, Zoonotic, and Atypical Infections
Pathogens of highly hazardous infections require immediate administration of potent targeted therapy:
- Yersinia pestis (plague): streptomycin, tetracyclines.
- Francisella tularensis (tularemia): streptomycin.
- Vibrio cholerae (cholera): doxycycline, ciprofloxacin.
- Brucella (brucellosis): combination of doxycycline and rifampin.
Intracellular and atypical pathogens are inaccessible to classical $\beta$-lactams, making other pharmacological groups the leading choices:
- Rickettsiae (epidemic typhus, Rocky Mountain spotted fever, Q fever) and Borrelia burgdorferi (Lyme disease): doxycycline.
- Chlamydia: doxycycline or azithromycin.
- Mycoplasma pneumoniae: macrolides or doxycycline.
- Legionella pneumophila: macrolides.
Spirochetes, particularly Treponema pallidum (the causative agent of syphilis), retain high susceptibility to benzylpenicillin.
Anaerobes, Fungi, and Specific Regimens
Clear therapeutic regimens have been developed for infections caused by specific pathogens:
- Anaerobes: For infections associated with Bacteroides fragilis, clindamycin or metronidazole is used. Clostridial infections require a differentiated approach: gas gangrene (Clostridium perfringens) and tetanus (Clostridium tetani) are treated with benzylpenicillin, whereas pseudomembranous colitis (Clostridium difficile) is treated with oral vancomycin or metronidazole.
- Pneumocystis: For the eradication of Pneumocystis jirovecii (formerly carinii), trimethoprim-sulfamethoxazole is the drug of choice.
- Helicobacter: Eradication of Helicobacter pylori is performed using combination therapy including amoxicillin and clarithromycin.
- Tuberculosis: Mycobacterium tuberculosis requires a prolonged multi-drug regimen whose core agents are isoniazid, rifampin, ethambutol, and pyrazinamide.